At a ceremony on December 8 in New Haven, CURE presented the 2015 CURE Entrepreneur of the Year Award to Milind Deshpande of Achillion Pharmaceuticals and Patrick Fourteau of New Haven Pharmaceuticals, two biotechnology executives whose companies have developed promising new pharmaceutical products through the expert management of new approaches to drug development.
According to a colleague and scientist familar with his work, “Milind has inspired and led extraordinary examples of innovation in the antiviral arena, culminating in the establishment of a world-class portfolio of early to mid stage compounds targeting Hepatitis C virus” and an important worldwide license and collaboration agreement with Janssen Pharmaceuticals.
According to an industry executive familar with his work, “Patrick is a visionary leader and motivator who also knows when to reshuffle the deck to make things work. Utilizing resources within Connecticut and elsewhere, he has led the company through its clinical trials, FDA approval, and launch of DURLAZA™, a breakthrough pharmaceutical product recently approved by the FDA.”
The CURE Entrepreneur of the Year Award was established by CURE and Shipman & Goodwin LLP in 2013 to acknowledge the importance of showcasing unique accomplishments of entrepreneurs in the Connecticut bioscience community.